1. Home
  2. Live Updates
  3. Ulmonary arterial hypertension

Live Breaking News & Updates on Ulmonary arterial hypertension

Stay informed with the latest breaking news from Ulmonary arterial hypertension on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Ulmonary arterial hypertension and stay connected to the pulse of your community

New Drug Helps Patients With High Blood Pressure of the Lungs Breathe Easier

The FDA has approved sotatercept (Winrevair), a first-in-kind drug to improve exercise tolerance and functional class and slow the progression of pulmonary arterial hypertension.

Michigan , United-states , Heather-kauffman , Vallerie-mclaughlin , Nick-blackmer , Verywell-health , University-of-michigan-health , Drug-administration , Pulmonary-arterial , Michigan-health , New-type , Pulmonary-hypertension

An ActRIIA fusion protein got FDA approved for PAH treatment

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment. PAH, characterized by elevated blood pressure in the arteries connecting the heart and lungs, poses a grave risk of heart failure.

Maria-osipova , Implications-across-disease , Protein , Lood , Lood-pressure , Eart , Eart-failure , Ungs , Ulmonary-arterial-hypertension , Eceptor , Esearch

Study finds improved survival in patients with SLE-associated PAH

A team from Peking Union Medical College Hospital in Beijing, China, have explored changes in the characteristics, treatment, and 5-year survival for SLE-associated PAH in the last decade, and possible reasons for survival change.

China , Peking , Beijing , Megan-craig , Union-medical-college-hospital , European-alliance-of-associations , Peking-union-medical-college-hospital , European-alliance , Hospital , Upus , Upus-erythematosus , Ortality

CardioGen upgrade facilitates more accurate diagnosis

Over 2,800 cases, representing a 31% increase, added to BGI Genomics-led CardioGen's hereditary cardiovascular disease gene data.

Shenzhen , Guangdong , China , Chinese , National-center , Association-for-molecular-pathology , American-college-of-medical-genetics-genomics , Key-laboratory-of-cardiovascular-diseases , Shenzhen-stock-exchange , Cardiovascular-diseases , Fuwai-hospital

Single tablet treatment on the horizon from Janssen for PAH

Patients with pulmonary arterial hypertension (PAH) may be able to take a single tablet instead of multiple types if a new drug is approved.

Drug-administration , Janssen-pharmaceutical-companies-of-johnson , European-society-of-cardiolgy , Janssen-pharmaceutical-companies , European-society , European-respiratory , Preclinical-research , Arkets-amp-regulations , Pis-active-pharmaceutical-ingredients- , Egulations , Ulmonary-arterial-hypertension

Woman describes being treated for rare, but often fatal heart condition

Pulmonary Arterial Hypertension is a rare, but often fatal disease where blood vessels in the lungs become narrower, blocked or destroyed.

Boston , Massachusetts , United-states , Katrina-barry , Jessica-brown , Aaron-waxman , Pulmonary-vascular-disease-program-at-brigham , Pulmonary-vascular-disease-program , Sotatercept-the , Righam-and-women-039s-hospital , Assachusetts , Erck

Fixed-dose combination therapy provides better results than monotherapy for pulmonary hypertension

Patients with pulmonary arterial hypertension (high blood pressure in the arteries that supply the lungs, also called PAH) had approximately double the reduction in pulmonary vascular resistance (PVR) if they took the PAH medications macitentan (10 mg) and tadalafil (40 mg) together in a single tablet rather than either drug alone, according to research being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology.

Dallas , Texas , United-states , Kelly-chin , Emily-henderson , Ut-southwestern-medical-center , Janssen-pharmaceutical-company-of-johnson , World-health-organization , Drug-administration , Actelion-pharmaceuticals-ltd , American-college , Annual-scientific-session-together-with

Addition of sotatercept to existing therapy shows promise for the treatment of pulmonary arterial hypertension

Patients with pulmonary arterial hypertension (PAH), a severe, progressive condition that affects the heart and lungs, who were treated with the novel first-in-class medication sotatercept on top of existing therapy experienced significant improvements in walking distance via a six-minute walking test—the study's primary endpoint and a validated surrogate for functional improvement and reduced symptom burden.

Germany , Mariusm-hoeper , Emily-henderson , Hannover-medical-school-in , Merck-co , Acceleron-pharma-inc , American-college , Annual-scientific-session-together-with , World-congress , Hannover-medical-school , Merck-sharp , New-england-journal

Heartpoint Global Hopes To Disrupt Pulmonary Hypertension Treatment With Minimally Invasive Device

A new treatment under development by HeartPoint Global seeks to provide a minimally invasive and cheaper alternative to current treatments for pulmonary arterial hypertension.

United-states , India , Israel , New-delhi , Delhi , Florida , Zurich , Züsz , Switzerland , Kyiv , Kyyiv , Misto

New biomaterial allows for treating damaged tissue from the inside out

A new biomaterial that can be injected intravenously, reduces inflammation in tissue and promotes cell and tissue repair.

United-states , Karen-christman , Martin-spang , Ryanr-reeves , Shu-chien , Emily-henderson , University-of-california-san-diego , Uc-san-diego-division-of-cardiovascular-medicine , Ventrix-bio-inc , California-san-diego , Nature-biomedical , Diego-division